Multi-omics Biomarker Analysis Identifies Unique Immune Activation Signature in Pancreatic Cancer

Multi-omics Biomarker Analysis Identifies Unique Immune Activation Signature in Pancreatic Cancer

Case Studies

We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.

Back to Resources overview

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact